Judge Gilstrap’s Test and an “Intervening Change in the Law”?: The Latest on Venue
Thousands of pending patent cases are now on uncertain ground [...]
FRAND and SEP Update: Asia
Standard essential patents (SEPs) are a key part of global [...]
Inevitable Disclosure, the DTSA, and Avoiding Contamination
The year-old federal Defend Trade Secrets Act (DTSA) expressly disavows [...]
Winning Attorney Fees: What Works, What Doesn’t
It has been three years since the U.S. Supreme Court decision [...]
IPO IP Innovation Dialog Trip to China
IPO IP Innovation Dialog Trip to China 22-27 October 2017 Registration [...]
Who Will “Dance” Now? Biosimilars After Amgen v. Sandoz
Developers for biosimilars face not only stiff technical and manufacturing challenges, but [...]
Exhaustion Unleashed: Licensing, Patenting Strategy, and Litigation After Lexmark
This webinar will explore the significant ramifications of the recent [...]
Venue Transfers and Section 1400(b) After Heartland
This webinar gathers three savvy patent litigators with deep knowledge [...]
Pharma Lessons from the PTAB: Litigation and Prosecution
After a slow start, AIA challenges are now a frequent [...]
On-Sale Bar After Helsinn: What is the Scope?
How can a recent Federal Circuit opinion on the on-sale [...]